You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

356 Results
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    letrozole
Dec 2025
Drug
Other Name(s): Xgeva®; Wyost™; Osenvelt™
Dec 2025
Drug
Other Name(s): Vitrakvi®
Dec 2025
Drug
Other Name(s): Darzalex®
Jan 2026
Drug
Other Name(s): Darzalex® SC
Jan 2026
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Jan 2026
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Daratumumab in Combination with a Bortezomib-Based Regimen for Newly Diagnosed Transplant Ineligible Multiple Myeloma
Jan 2026
Regimen
Cancer Type:
Hematologic, 
Amyloidosis, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Daratumumab in Combination with a Bortezomib-Based Regimen for Newly Diagnosed Transplant Ineligible Multiple Myeloma
New Drug Funding Program
    Daratumumab - In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma
New Drug Funding Program
    Daratumumab and Bortezomib in combo with Cyclophosphamide and Dexamethasone - Previously Untreated Light Chain (AL) Amyloidosis
Jan 2026
Drug
Other Name(s): Cosmegen®
Feb 2026

Pages